Alzheimer’s Vaccine Efforts Being Abandoned for Wrong Reasons, Researcher Argues

Alzheimer’s Vaccine Efforts Being Abandoned for Wrong Reasons, Researcher Argues
Vaccine development strategies for Alzheimer’s disease should attempt to mirror the natural immunity against toxic amyloid-beta, instead of venturing on uncertain paths, Dr. Dante Marciani argued in a feature article discussing Alzheimer’s disease vaccine development. The feature, “Rejecting the Alzheimer’s disease vaccine development for the wrong reasons,” which recently appeared in the journal Drug Discovery Today, cautioned about abandoning vaccine development attempts in light of failed trials, since the reason for failure is not a flawed theory, but misguided treatment design. This is not the first time Marciani — who is the president and CSO at Qantu Therapeutics, with more than 30 years of experience in immunotherapy and vaccine development — attempts to draw attention to what he calls the skewed turns of Alzheimer’s drug development. He published an extensive retrospective in April highlighting the mistakes he thinks have prevented amyloid research being translated successfully into a treatment. Now, more than six months later, he does not see the change he was hoping for. The wrong targets and methods are still being used, he said, with no lessons learned from clinical trial failures. Lifting a radically different example, Marciani told Alzheimer’s News Today that it took Zika virus scientists less than nine months to discover that the wrong viral antigen caused an unfavorable i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *